Pharmaceuticals
Biocon Malaysia Recognised Across Five Categories at MOPI Pharma Industry Awards 2026
JOHOR BAHRU, Malaysia, Nov. 4, 2026 /PRNewswire/ -- Biocon Sdn. Bhd., Malaysia (Biocon Malaysia),a stepdown subsidiary of global biopharmaceuticals company Biocon Limited, has been recognised across five categories at the second edition of Malaysian Organisation of Pharmaceutical Industries' (MOP...
2026-11-04 11:15
2339
Samsung Biologics Achieves 'Negligible Risk' Rating in Sustainalytics ESG Assessment
* Earns ESG Risk Rating score of 9.0, ranking among the top 0.5% in the pharmaceuticals industry * Advances from 'Low Risk' to 'Negligible Risk,' the lowest ESG risk category * Recognition reflects continued improvements in ESG risk management across operations INCHEON, South Korea, Nov. 3, ...
2026-11-04 07:30
2532
Zuellig Pharma Strengthens Clinical Sourcing Capabilities in China through Strategic Acquisition
The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across China HANGZHOU, China, Nov. 3, 2026 /PRNewswire/ -- Zuellig Pharma, a leading healthcare solutions company in Asia, announced the strategic acqu...
2026-11-04 07:00
1985
Zuellig Pharma Strengthens Clinical Sourcing Capabilities in China through Strategic Acquisition
The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across China HANGZHOU, China, Nov. 4, 2026 /PRNewswire/ -- Zuellig Pharma, a leading healthcare solutions company in Asia, announced the strategic acqu...
2026-11-04 07:00
2021
MoleculeMind's New MMDesign Technical Report Demonstrates 94.7% Campaign Success Rate Across Diverse Molecular Targets and Modalities
SHANGHAI, Nov. 3, 2026 /PRNewswire/ -- MoleculeMind
2026-11-03 23:00
5918
Differentia Bio Advances Human Digital Twins with AI-Driven Disease Modeling and Clinical Validation
From millions of molecular measurements to clinically supported therapeutic predictions, Differentia is building AI-powered disease environments for pharmaceutical R&D. SAN FRANCISCO, Nov. 3, 2026 /PRNewswire/ -- Differentia Bio, a developer of AI-powered human disease digital twins, today annou...
2026-11-03 18:48
1976
SIRONA 3-Year Results: Sirolimus-Coated Balloon Shows Higher Freedom From Repeat Revascularization Than Paclitaxel-Coated Balloons in Femoropopliteal Disease
Late-breaking data presented at TCT 2026
2026-11-03 18:39
2411
Laboratoires Pierre Fabre announces the approval of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer with a BRAFV600E mutation in Singapore
* New targeted treatment option now available in for adult patients with BRAF V600E mutant advanced non-small cell lung cancer (NSCLC) * Launch follows European approval based on results from the Phase II PHAROS trial, demonstrating meaningful clinical benefit to patients with a high objective...
2026-11-03 10:00
4679
Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
BEIJING, Nov. 2, 2026 /PRNewswire/ -- Brise Pharmaceuticals Co., Ltd. (Brise) today provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under the terms of the collaboration agreement, Brise is responsible for discovery efforts and A...
2026-11-02 22:00
2826
Ractigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder Cancer
* Trial initiated at Fudan University Shanghai Cancer Center (FUSCC) under the leadership of Leading Principal Investigator Professor Ding-Wei Ye, uniting 11 premier urologic oncology centers across China * Phase II study incorporates a safety run-in phase with a subsequent multi-cohort desig...
2026-11-02 21:25
2678
Sirolimus-Coated Balloon Matches Drug-Eluting Stent at One Year in Large International TRANSFORM II Trial
Late-breaking results presented at TCT 2026 show an implant-free strategy with MagicTouch Sirolimus Coated Balloon is non-inferior to everolimus-eluting in de novo coronary artery disease TAMPA, Florida, Nov. 2, 2026 /PRNewswire/ -- Sirolimus-coated balloon (SCB) strategy was non-inferior to con...
2026-11-02 21:22
2380
InventisBio Announces Topline Results of a Phase III Study of Nomelcitinib (TYK2 Inhibitor), Demonstrating Promising Efficacy and Safety in Patients with Moderate to Severe Plaque Psoriasis.
SHANGHAI, Nov. 2, 2026 /PRNewswire/ -- InventisBio Co., Ltd. today announced that itsJH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key secondary endpoint in a registrational Phase III clinical trial for the treatment of moderate-to-severe plaque psor...
2026-11-02 19:00
3890
Lynk Pharmaceuticals Announces Commercialization Collaboration with Simcere for Zemprocitinib in Dermatology Indications, Further Expanding Product Commercialization Footprint
HANGZHOU, China, SHANGHAI and BOSTON, Nov. 2, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), today announced that it has expanded its commercialization collaboration with Simcere Pharmaceutical Group Limited ("Simcere") for zemprocitinib, a highly selective, oral, ...
2026-11-02 17:00
2869
Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026
- Poster presentations feature preclinical in vitro and in vivo data of potentially first-in-class oral small molecule GIPR agonist ASC48 and next-generation once-monthly to once-quarterly GLP-1R/GIPR/GCGR triple peptide agonist ASC37 HONG KONG, Nov. 2, 2026 /PRNewswire/ -- Ascletis Pharma Inc. ...
2026-11-02 16:50
2945
Bracco Convenes Global CEUS Steering Committee to Strengthen International Collaboration and Help Shape the Future of Contrast-Enhanced Ultrasound
Second edition of the global CEUS Steering Committee brings together multidisciplinary experts to exchange scientific perspectives, identify emerging clinical and research opportunities and inform future evidence generations. LOMBARDY, Italy, Nov. 2, 2026 /PRNewswire/ -- Bracco convened the seco...
2026-11-02 16:00
2158
Self-Care Momentum Builds Across Asia-Pacific: Regional collaboration drives progress across health literacy, Regulatory streamlining and Leveraging Digital Solutions
BALI, Indonesia, Nov. 2, 2026 /PRNewswire/ -- Self-care is gaining momentum across Asia-Pacific, with more than 140 self-care initiatives aligned with the 2024 Bangkok Joint Initiative reported across the region in 2025 and 2026. Spanning health literacy, digital solutions, collaboration and stro...
2026-11-02 15:10
2740
Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.
SHANGHAI, Oct. 31, 2026 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma")announced today that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS), has successfullycompleted patient ...
2026-10-31 13:00
7199
Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"
BOSTON, Oct. 30, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. J...
2026-10-31 00:00
4967
Nuance Pharma Announces First Patient Dosed in REACH Phase III Trial of STG320 (Actair®) in China
SHANGHAI, Oct. 30, 2026 /PRNewswire/ -- Nuance Pharma announced that the first patient has been dosed in the REACH Phase III clinical trial evaluating STG320 (Actair®) for the treatment of house dust mite-induced allergic rhinitis in China. Stallergenes Greer's Actair® is a sublingual tablet cur...
2026-10-30 19:14
3989
Cambrex Breaks Ground on $120 Million Expansion in Charles City, Iowa
EAST RUTHERFORD, N.J., Oct. 30, 2026 /PRNewswire/ -- Cambrex, a leading global
contract development and manufacturing organization (CDMO), today marked the
groundbreaking of its $120 million expansion at its Charles City, Iowa facility.
2026-10-30 18:00
3393
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1169 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1130 media titles]
2026-11-05 06:52Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1118 media titles]
2026-11-06 22:06
Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00NYSE Chair Sharon Bowen Earns Lifetime Achievement Award: NYSE Content Update
[Picked up by 1073 media titles]
2026-11-05 22:05
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
64029
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
60884
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
57146
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
26632
